Cardiac arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discovery

Expert Opinion on Drug Discovery

Volumn 5, Issue 7, 2010, Pages 619-632

  MacRae, Calum A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Arrhythmogenesis; Cardiac arrhythmia; Functional genomics; in vivo screening; Zebrafish

Indexed keywords

AMIODARONE; DOFETILIDE; ION CHANNEL;

ARRHYTHMOGENESIS; CELL COMMUNICATION; CELL HETEROGENEITY; DRUG TARGETING; GENOMICS; HEART ARRHYTHMIA; HEART RHYTHM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCREENING; ZEBRA FISH;

EID: 77953708536     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.492826     Document Type: Review

References (117)

1. Wellens HJ. Cardiac arrhythmias: the quest for a cure: a historical perspective. J Am Coll Cardiol 2004;44(6):1155-1163
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-1022
3. The cardiac arrhythmia suppression trial. N Engl J Med 1989;321(25):1754-1756
4. Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J 2006;151(4):771-778
5. Waldo AL. Mechanisms of atrial fibrillation. J Cardiovasc Electrophysiol 2003;14(Suppl 12):S267-74
6. Eckardt L, Haverkamp W, Johna R, et al. Arrhythmias in heart failure: current concepts of mechanisms and therapy. J Cardiovasc Electrophysiol 2000;11(1):106-117
7. Roden DM. Mechanisms and management of proarrhythmia. Am J Cardiol 1998;82(4A):49I-57I
8. Ruskin JN. The cardiac arrhythmia suppression trial (CAST). N Engl J Med 1989;321(6):386-388
9. Spooner PM, Albert C, Benjamin EJ, et al. Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a national heart, lung, and blood institute workshop, part I. Circulation 2001;103(19):2361-2364
10. MacRae CA, Ellinor PT. Genetic screening and risk assessment in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44(12):2326-2328
11. Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002;11(3):337-345
12. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104(4):569-580
13. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110(9):1042-1046
14. Shah M, Akar FG, Tomaselli GF. Molecular basis of arrhythmias. Circulation 2005;112(16):2517-2529
15. Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002;105(25):2992-2997
16. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005;85(4):1205-1253
17. Roden DM, Balser JR, George AL Jr, et al. Cardiac ion channels. Annu Rev Physiol 2002;64:431-475
18. Salama G, London B. Mouse models of long QT syndrome. J Physiol 2007;578(Pt 1):43-53
19. Casimiro MC, Knollmann BC, Yamoah EN, et al. Targeted point mutagenesis of mouse Kcnq1: phenotypic analysis of mice with point mutations that cause Romano-Ward syndrome in humans. Genomics 2004;84(3):555-564
20. Emmi A, Wenzel HJ, Schwartzkroin PA, et al. Do glia have heart?. Expression and functional role for ether-a-go-go currents in hippocampal astrocytes. J Neurosci 2000;20(10):3915-3925
21. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99(4):529-533
22. Koren G. Electrical remodeling and arrhythmias in long-QT syndrome: lessons from genetic models in mice. Ann Med 2004;36(Suppl 1):22-27
23. Ali RH, Zareba W, Moss AJ, et al. Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol 2000;85(4):457-461
24. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103(1):89-95
25. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299(5604):251-254
26. Otway R, Vandenberg JI, Guo G, et al. Stretch-sensitive KCNQ1 mutation A link between genetic and environmental factors in the pathogenesis of atrial fibrillation? J Am Coll Cardiol 2007;49(5):578-586
27. MacRae CA. Closer look at genetic testing in long-QT syndrome: will DNA diagnostics ever be enough? Circulation 2009;120(18):1745-1748
28. Jentsch TJ, Hubner CA, Fuhrmann JC. Ion channels: function unravelled by dysfunction. Nat Cell Biol 2004;6(11):1039-1047
29. Ficker E, Dennis AT, Wang L, et al. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 2003;92(12):e87-100
30. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003;421(6923):634-639
31. Mohler PJ, Splawski I, Napolitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci USA 2004;101(24):9137-9142
32. Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006;114(20):2104-2112
33. Petrecca K, Atanasiu R, Akhavan A, et al. N-linked glycosylation sites determine HERG channel surface membrane expression. J Physiol 1999;515(Pt 1):41-48
34. Furutani M, Trudeau MC, Hagiwara N, et al. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation 1999;99(17):2290-2294
35. Kiss E, Nagy P, Balogh A, et al. Cytometry of raft and caveola membrane microdomains: from flow and imaging techniques to high throughput screening assays. Cytometry A 2008;73(7):599-614
36. Milan DJ, Kim AM, Winterfield JR, et al. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 2009;120(7):553-559
37. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997;30(6):1512-1520
38. Sen-Chowdhry S, Syrris P, McKenna WJ. Desmoplakin disease in arrhythmogenic right ventricular cardiomyopathy: early genotype-phenotype studies. Eur Heart J 2005;26(16):1582-1584
39. Coonar AS, Protonotarios N, Tsatsopoulou A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation 1998;97(20):2049-2058
40. Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002;71(5):1200-1206
41. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004;36(11):1162-1164
42. Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet 2006;79(5):978-984
43. Heuser A, Plovie ER, Ellinor PT, et al. Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2006;79(6):1081-1088
44. Asimaki A, Syrris P, Wichter T, et al. A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2007;81(5):964-973
45. Garcia-Gras E, Lombardi R, Giocondo MJ, et al. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006;116(7):2012-2021
46. Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2009;360(11):1075-1084
47. Nattel S, Shiroshita-Takeshita A, Cardin S, et al. Mechanisms of atrial remodeling and clinical relevance. Curr Opin Cardiol 2005;20(1):21-25
48. Brundel BJ, Henning RH, Kampinga HH, et al. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002;54(2):315-324
49. Sack MN, Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms [review]. Int J Mol Med 1998;1(1):17-24
50. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7(8):589-600
51. McNally EM, Pytel P. Muscle diseases: the muscular dystrophies. Annu Rev Pathol 2007;2:87-109
52. Kass RS, Kurokawa J, Marx SO, et al. Leucine/isoleucine zipper coordination of ion channel macromolecular signaling complexes in the heart. Roles in inherited arrhythmias. Trends Cardiovasc Med 2003;13(2):52-56
53. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003;4(7):517-529
54. Feillet F, Steinmann G, Vianey-Saban C, et al. Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive Care Med 2003;29(9):1594-1597
55. Antzelevitch C, Fish J. Electrical heterogeneity within the ventricular wall. Basic Res Cardiol 2001;96(6):517-527
56. Christoffels VM, Burch JB, Moorman AF. Architectural plan for the heart: early patterning and delineation of the chambers and the nodes. Trends Cardiovasc Med 2004;14(8):301-307
57. de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988;77(3):589-606
58. van der Merwe PL, Rose AG, van der Walt JJ, et al. Progressive familial heart block type I. Clinical and pathological observations. S Afr Med J 1991;80(1):34-38
59. Brink PA, Ferreira A, Moolman JC, et al. Gene for progressive familial heart block type I maps to chromosome 19q13. Circulation 1995;91(6):1633-1640
60. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101(5):510-515
61. Weiss R, Barmada MM, Nguyen T, et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation 2002;105(6):707-713
62. Antzelevitch C, Yan GX, Shimizu W. Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J Electrocardiol 1999;32(Suppl):158-165
63. Costantini DL, Arruda EP, Agarwal P, et al. The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell 2005;123(2):347-358
64. Heydemann A, Huber JM, Kakkar R, et al. Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol 2004;36(2):213-223
65. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96(4):1180-1184
66. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007;50(21):2021-2028
67. Ramos-Mondragon R, Galindo CA, Avila G. Role of TGF-beta on cardiac structural and electrical remodeling. Vasc Health Risk Manag 2008;4(6):1289-1300
68. Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 2008;65(10):1489-1508
69. Ellinor PT, Sasse-Klaassen S, Probst S, et al. A novel locus for dilated cardiomyopathy, diffuse myocardial fibrosis, and sudden death on chromosome 10q25-26. J Am Coll Cardiol 2006;48(1):106-111
70. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000;15(4):264-272
71. Wu SM, Chien KR, Mummery C. Origins and fates of cardiovascular progenitor cells. Cell 2008;132(4):537-543
72. Ahuja P, Sdek P, MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 2007;87(2):521-544
73. Milan DJ, MacRae CA. Animal models for arrhythmias. Cardiovasc Res 2005;67(3):426-437
74. Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145(10):749-757
75. Rutitzky B, Girotti AL, Rosenbaum MB. Efficacy of chronic amiodarone therapy in patients with variant angina pectoris and inhibition of ergonovine coronary constriction. Am Heart J 1982;103(1):38-43
76. Zhang S, Zhou Z, Gong Q, et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999;84(9):989-998
77. Kaski JC, Girotti LA, Elizari MV, et al. Efficacy of amiodarone during long-term treatment of potentially dangerous ventricular arrhythmias in patients with chronic stable ischemic heart disease. Am Heart J 1984;107(4):648-655
78. Strange K. The end of "naive reductionism": rise of systems biology or renaissance of physiology? Am J Physiol Cell Physiol 2005;288(5):C968-74
79. Ge H, Walhout AJ, Vidal M. Integrating 'omic' information: a bridge between genomics and systems biology. Trends Genet 2003;19(10):551-560
80. Giallourakis C, Henson C, Reich M, et al. Disease gene discovery through integrative genomics. Annu Rev Genomics Hum Genet 2005;6:381-406
81. Li S, Armstrong CM, Bertin N, et al. A map of the interactome network of the metazoan C. elegans. Science 2004;303(5657):540-543
82. Rudy Y. From genome to physiome: integrative models of cardiac excitation. Ann Biomed Eng 2000;28(8):945-950
83. Verrier RL, Antzelevitch C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 2004;19(1):2-11
84. Berger SI, Ma'ayan A, Iyengar R. Systems pharmacology of arrhythmias. Sci Signal 2010;3(118):ra30
85. Cheng CS, Alderman D, Kwash J, et al. A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev Ind Pharm 2002;28(2):177-191
86. Casimiro MC, Knollmann BC, Ebert SN, et al. Targeted disruption of the Kcnq1 gene produces a mouse model of Jervell and Lange-Nielsen Syndrome. Proc Natl Acad Sci USA 2001;98(5):2526-2531
87. Nerbonne JM. Studying cardiac arrhythmias in the mouse - a reasonable model for probing mechanisms? Trends Cardiovasc Med 2004;14(3):83-93
88. Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 2008;41(Suppl 1):51-56
89. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-676
90. Domian IJ, Chiravuri M, van der Meer P, et al. Generation of functional ventricular heart muscle from mouse ventricular progenitor cells. Science 2009;326(5951):426-429
91. Potet F, Petersen CI, Boutaud O, et al. Genetic screening in C. elegans identifies rho-GTPase activating protein 6 as novel HERG regulator. J Mol Cell Cardiol 2009;46(2):257-267
92. Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. Bioessays 2003;25(9):904-912
93. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet 2007;8(5):353-367
94. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005;4(1):35-44
95. MacRae CA, Peterson RT. Zebrafish-based small molecule discovery. Chem Biol 2003;10(10):901-908
96. Burns CG, Milan DJ, Grande EJ, et al. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat Chem Biol 2005;1(5):263-264
97. Milan DJ, Peterson TA, Ruskin JN, et al. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003;107(10):1355- 1358
98. Fishman MC. Genomics. Zebrafish - the canonical vertebrate. Science 2001;294(5545):1290-1291
99. Nasevicius A, Ekker SC. Effective targeted gene 'knockdown' in zebrafish. Nat Genet 2000;26(2):216-220
100. Meng X, Noyes MB, Zhu LJ, et al. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol 2008;26(6):695-701
101. Driever W, Solnica-Krezel L, Schier AF, et al. A genetic screen for mutations affecting embryogenesis in zebrafish. Development 1996;123:37-46
102. Kokel D, Bryan J, Laggner C, et al. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol 2010;6(3):231-237
103. Yeh JR, Munson KM, Chao YL, et al. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 2008;135(2):401-410
104. Peterson RT, Shaw SY, Peterson TA, et al. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat Biotechnol 2004;22(5):595-599
105. Cuny GD, Yu PB, Laha JK, et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 2008;18(15):4388-4392
106. Lee JS, Yu Q, Shin JT, et al. Klf2 is an essential regulator of vascular hemodynamic forces in vivo. Dev Cell 2006;11(6):845-857
107. Langheinrich U, Vacun G, Wagner T. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol Appl Pharmacol 2003;193(3):370-382
108. Baker K, Warren KS, Yellen G, et al. Defective "pacemaker" current (Ih) in a zebrafish mutant with a slow heart rate. Proc Natl Acad Sci USA 1997;94(9):4554-4559
109. Milan DJ, Jones IL, Ellinor PT, et al. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am J Physiol Heart Circ Physiol 2006;291(1):H269-73
110. Shin JT, Pomerantsev EV, Mably JD, et al. High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafish. Physiol Genomics 2010. [Epub ahead of print]
111. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005;2(7):758-772
112. Lupoglazoff JM, Cheav T, Baroudi G, et al. Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block. Circ Res 2001;89(2):E16-21
113. Ho SY, Thorpe JL, Deng Y, et al. Lipid metabolism in zebrafish. Methods Cell Biol 2004;76:87-108
114. Weinstein BM. What guides early embryonic blood vessel formation? Dev Dyn 1999;215(1):2-11
115. Shin JT, Fishman MC. From Zebrafish to human: modular medical models. Annu Rev Genomics Hum Genet 2002;3:311-340
116. Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 2008;14(12):1363-1369
117. Berghmans S, Butler P, Goldsmith P, et al. Zebrafish based assays for the assessment of cardiac, visual and gut function - potential safety screens for early drug discovery. J Pharmacol Toxicol Methods 2008;58(1):59-68